EBITDA margins improved significantly in both lab tech and med tech, with strong cash flow reducing leverage to 2.8x EBITDA. Revenue growth was robust in most geographies, and the acquisition of Edge Medical supports a more active M&A agenda.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.